Your browser doesn't support javascript.
loading
Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
Álvarez-Twose, Iván; Jara-Acevedo, María; Morgado, José Mário; García-Montero, Andrés; Sánchez-Muñoz, Laura; Teodósio, Cristina; Matito, Almudena; Mayado, Andrea; Caldas, Carolina; Mollejo, Manuela; Orfao, Alberto; Escribano, Luis.
Afiliação
  • Álvarez-Twose I; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain. Electronic address: ivana@sescam.jccm.es.
  • Jara-Acevedo M; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría-NUCLEUS, University of Salamanca, Salamanca, Spain.
  • Morgado JM; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • García-Montero A; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría-NUCLEUS, University of Salamanca, Salamanca, Spain.
  • Sánchez-Muñoz L; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Teodósio C; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría-NUCLEUS, University of Salamanca, Salamanca, Spain.
  • Matito A; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Mayado A; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría-NUCLEUS, University of Salamanca, Salamanca, Spain.
  • Caldas C; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría-NUCLEUS, University of Salamanca, Salamanca, Spain.
  • Mollejo M; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Pathology Department, Hospital Virgen de la Salud, Toledo, Spain.
  • Orfao A; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría-NUCLEUS, University of Salamanca, Salamanca, Spain.
  • Escribano L; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
J Allergy Clin Immunol ; 137(1): 168-178.e1, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26100086
ABSTRACT

BACKGROUND:

Well-differentiated systemic mastocytosis (WDSM) is a rare variant of systemic mastocytosis (SM) characterized by bone marrow (BM) infiltration by mature-appearing mast cells (MCs) often lacking exon 17 KIT mutations. Because of its rarity, the clinical and biological features of WDSM remain poorly defined.

OBJECTIVE:

We sought to determine the clinical, biological, and molecular features of a cohort of 33 patients with mastocytosis in the skin in association with BM infiltration by well-differentiated MCs and to establish potential diagnostic criteria for WDSM.

METHODS:

Thirty-three patients with mastocytosis in the skin plus BM aggregates of round, fully granulated MCs lacking strong CD25 and CD2 expression in association with clonal MC features were studied.

RESULTS:

Our cohort of patients showed female predominance (female/male ratio, 41) and childhood onset of the disease (91%) with frequent familial aggregation (39%). Skin involvement was heterogeneous, including maculopapular (82%), nodular (6%), and diffuse cutaneous (12%) mastocytosis. KIT mutations were detected in only 10 (30%) of 33 patients, including the KIT D816V (n = 5), K509I (n = 3), N819Y (n = 1), and I817V (n = 1) mutations. BM MCs displayed a unique immunophenotypic pattern consisting of increased light scatter features, overexpression of cytoplasmic carboxypeptidase, and aberrant expression of CD30, together with absent (79%) or low (21%) positivity for CD25, CD2, or both. Despite only 9 (27%) of 33 patients fulfilling the World Health Organization criteria for SM, our findings allowed us to establish the systemic nature of the disease, which fit with the definition of WDSM.

CONCLUSIONS:

WDSM represents a rare clinically and molecularly heterogeneous variant of SM that requires unique diagnostic criteria to avoid a misdiagnosis of cutaneous mastocytosis per current World Health Organization criteria.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mastocitose Cutânea / Mastocitose Sistêmica Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mastocitose Cutânea / Mastocitose Sistêmica Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2016 Tipo de documento: Article